Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis.

ABSTRACT:

Introduction

This analysis aimed to investigate the effectiveness and safety profile of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in clinical practice.

Methods

Clinical records of patients diagnosed with mild-to-moderate IPF (as per European Medicines Agency indication) and receiving pirfenidone treatment across three centers in Belgium and the Netherlands between April 2011 and October 2013 were retrospectively collected from patient notes at 3-month intervals. Pulmonary function measurements, including % predicted forced vital capacity (%FVC) and % predicted diffusing capacity of the lungs for carbon monoxide (%DLCO), were analyzed from 6 months prior to pirfenidone treatment up to 12 months of treatment. Decline in lung function, defined as an a

SUBMITTER: Wijsenbeek MS 

PROVIDER: S-EPMC4522034 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature